Clinical trials have demonstrated that gefitinib is particularly effective in patients with advanced NSCLC harboring EGFR mutations. Studies have shown that it can significantly improve progression-free survival compared to traditional chemotherapy. However, resistance to gefitinib can develop over time, often due to additional genetic changes in the cancer cells.
